H.I.G. buys BioVectra for US$250M

Charlottetown-based drug manufacturer BioVectra is being sold to U.S. private equity firm H.I.G. Capital for as much as US$250 million (C$330 million) – more than three times the price it sold for almost six years ago.
BioVectra’s owner, British pharmaceutical company Mallinckrodt plc, issued a statement on Tuesday saying it had agreed to the sale. The price includes both a fixed payment now and